30 closest matches · ranked by relevance
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Head and Neck Neoplasms
Primary: Progression-Free Survival (PFS) — 5.1 months
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 4.4 months
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Cancer · Carcinoma · Head and Neck Cancer
Primary: Objective Response Rate — 3.9 percentage of participants
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria — 6.7; 0 percentage of participants
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 60 percentage of participants
Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Larynx · Squamous Cell Carcinoma of the Oral Cavity
Primary: Phase I: Maximum Tolerated Dose — 500 mg/m^2
Squamous Cell Carcinoma of the Head and Neck
Primary: Best Overall Response (BOR) According to Modified World Health Organization (WHO) Criteria — 36.4 percentage of participants
Head and Neck Squamous Cell Carcinoma · Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma · Recurrent Nasopharynx Carcinoma
Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 1; 1; 0; 1 Participants
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Head and Neck Cancer
Primary: Response Probability (Confirmed Complete and Partial Responses) — 0; 2; 38 participants
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Overall Response Rate — 1; 8 participants
Recurrent and/or Metastatic Head and Neck Cancer
Primary: Overall Survival — 11.1; 9.0 months — p=0.1403
Stage IV Squamous Cell Carcinoma of the Hypopharynx · Stage IV Squamous Cell Carcinoma of the Larynx · Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Primary: Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease) — 2; 9; 2 participants
Head and Neck Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants — 16.4 Percentage of participants — p=<0.001
Metastatic Squamous Cell Carcinoma of the Hypopharynx · Metastatic Squamous Cell Carcinoma of the Larynx · Metastatic Squamous Cell Carcinoma of the Oral Cavity
Primary: Progression Free Survival (PFS) — 6.08; 4.4 months
Head and Neck Cancer
Primary: Progression-Free Survival (PFS) — 1.9; 2.0 months — p=0.0667
Head and Neck Cancer
Primary: Objective Response Rate (ORR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup — 13.2; 18.3 percentage of participants — p=0.2897
Head and Neck Basaloid Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.8; 3.7 months — p=.04
Head and Neck Cancer
Primary: Overall Response Rate — 0 patients
Head and Neck Cancer
Primary: Overall Objective Response — 4; 18; 2; 1 participants
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Salivary Gland Cancer
Primary: Antitumor Activity of SB-715992 Using Objective Response Rates (Partial and Complete Responses) — 0 participants